The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
Objective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA).Subjects and methods. The investigation enrolled 102 patients (78 women and 24 men, aged 23 – 70 years), including 72 patients with RA and 30 people wi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2015-08-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/384 |
| _version_ | 1826567521510096896 |
|---|---|
| author | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov |
| author_facet | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov |
| author_sort | M. S. Naumtseva |
| collection | DOAJ |
| description | Objective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA).Subjects and methods. The investigation enrolled 102 patients (78 women and 24 men, aged 23 – 70 years), including 72 patients with RA and 30 people without systemic inflammatory rheumatic diseases (a control group) who had a recent history of 2 and more cases of lower respiratory tract infections (bronchitis, pneumonia). When included, all the patients received anti-inflammatory therapy with methotrexate (MT) (n = 52), leflunomide (LEF) (n = 10), or MT + tumor necrosis factor-α (TNF-α ) inhibitors (n = 10). A single 0.5-ml dose of the 23-valent pneumococcal vaccine was administered subcutaneously during continuous MT or LEF therapy for the underlying disease or 3 – 4 weeks before the use of a TNF-α inhibitor. During control visits (1 and 3 months and 1 year after administration of the vaccine), the patients underwent physical examination and routine clinical and laboratory studies.Results. No clinical and radiological symptoms of pneumonia were recorded in any case during a 12-month follow-up. The RA and control groups showed a more than 2-fold increase in anti-pneumococcal antibody levels 1 year after vaccination. The vaccine was well tolerated by 67 patients. 27 patients were observed to have pain, cutaneous swelling and hyperemia and 8 patients had subfebrility. There were neither episodes of RA exacerbation nor new autoimmune disorders during the follow-up.Conclusion. The findings suggest that 23-valent pneumococcal vaccine shows a good clinical efficacy, adequate immunogenicity, and good tolerability in the patients with RA. |
| first_indexed | 2024-04-10T02:51:57Z |
| format | Article |
| id | doaj.art-38b0e00f119347a1a2c46df7bd312581 |
| institution | Directory Open Access Journal |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| last_indexed | 2025-03-14T11:08:52Z |
| publishDate | 2015-08-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj.art-38b0e00f119347a1a2c46df7bd3125812025-03-02T10:40:25ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942015-08-01144677310.31631/2073-3046-2015-14-4-67-73383The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid ArthritisM. S. Naumtseva0B. S. Belov1G. M. Tarasova2D. E. Karateev3E. L. Luchikhina4Yu. V. Muravyev5E. N. Aleksandrova6A. A. Novikov7V.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Moscow Nasonova Research Institute of RheumatologyObjective: to study the clinical efficacy, immunogenicity, and safety of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis (RA).Subjects and methods. The investigation enrolled 102 patients (78 women and 24 men, aged 23 – 70 years), including 72 patients with RA and 30 people without systemic inflammatory rheumatic diseases (a control group) who had a recent history of 2 and more cases of lower respiratory tract infections (bronchitis, pneumonia). When included, all the patients received anti-inflammatory therapy with methotrexate (MT) (n = 52), leflunomide (LEF) (n = 10), or MT + tumor necrosis factor-α (TNF-α ) inhibitors (n = 10). A single 0.5-ml dose of the 23-valent pneumococcal vaccine was administered subcutaneously during continuous MT or LEF therapy for the underlying disease or 3 – 4 weeks before the use of a TNF-α inhibitor. During control visits (1 and 3 months and 1 year after administration of the vaccine), the patients underwent physical examination and routine clinical and laboratory studies.Results. No clinical and radiological symptoms of pneumonia were recorded in any case during a 12-month follow-up. The RA and control groups showed a more than 2-fold increase in anti-pneumococcal antibody levels 1 year after vaccination. The vaccine was well tolerated by 67 patients. 27 patients were observed to have pain, cutaneous swelling and hyperemia and 8 patients had subfebrility. There were neither episodes of RA exacerbation nor new autoimmune disorders during the follow-up.Conclusion. The findings suggest that 23-valent pneumococcal vaccine shows a good clinical efficacy, adequate immunogenicity, and good tolerability in the patients with RA.https://www.epidemvac.ru/jour/article/view/384rheumatoid arthritisautoimmune diseasescomorbid infectionscomorbiditypneumoniabronchitispneumococcal vaccinevaccinationimmunogenicityefficacytolerability |
| spellingShingle | M. S. Naumtseva B. S. Belov G. M. Tarasova D. E. Karateev E. L. Luchikhina Yu. V. Muravyev E. N. Aleksandrova A. A. Novikov The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis Эпидемиология и вакцинопрофилактика rheumatoid arthritis autoimmune diseases comorbid infections comorbidity pneumonia bronchitis pneumococcal vaccine vaccination immunogenicity efficacy tolerability |
| title | The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis |
| title_full | The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis |
| title_fullStr | The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis |
| title_full_unstemmed | The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis |
| title_short | The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis |
| title_sort | use of 23 valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis |
| topic | rheumatoid arthritis autoimmune diseases comorbid infections comorbidity pneumonia bronchitis pneumococcal vaccine vaccination immunogenicity efficacy tolerability |
| url | https://www.epidemvac.ru/jour/article/view/384 |
| work_keys_str_mv | AT msnaumtseva theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT bsbelov theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT gmtarasova theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT dekarateev theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT elluchikhina theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT yuvmuravyev theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT enaleksandrova theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT aanovikov theuseof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT msnaumtseva useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT bsbelov useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT gmtarasova useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT dekarateev useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT elluchikhina useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT yuvmuravyev useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT enaleksandrova useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis AT aanovikov useof23valentpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis |